title: Influence of sodium monoketocholate on the hypolipidemic activity of lovastatin in healthy and diabetic rats.
abstract: Recent findings regarding the physiological transport mechanisms and metabolism of bile acids have led to an increased interest in their synthetic derivatives, especially as transmucous transporters. The aim of this study was to examine the influence of the synthetic sodium salt of monoketocholic acid (Na-MKHA) on the hypolipidemic activity of lovastatin. The effects of a 7 days administration of lovastatin (20 mg/kg b.w.) (experimental group 1, n=5) and a combination of lovastatin (20 mg/kg b.w.) and Na-MKHA (2 mg/kg b.w.) (experimental group 2, n=5) in group of healthy and diabetic male Wistar rats were investigated. The animals in the control group of healthy (n=5) and diabetic (n=5) rats were treated with physiological saline (10 ml/kg b.w.) per os twice a day. In the healthy rats, lovastatin increased the low density lipoprotein (LDL) (32.14%) and non-high density lipoprotein (HDL) (15.38%) cholesterol and decreased HDL cholesterol levels (9.89%), and also increased the investigated atherogenic ratios. Na-MKHA significantly potentiated lovastatin activity, and its effects on the LDL (p<0.05; 102.70%), HDL (p<0.01; 32.93%) and non-HDL (p<0.05; 65%) cholesterol levels, as well as the LDL/HDL (p<0.02; 231.11%), total cholesterol/HDL (p<0.02; 70.52%) and non-HDU/HDL cholesterol ratios (p<0.02; 167.12%). In diabetic animals, the potentiating effect of Na-MKHA was not significant. The stimulatory effect of Na-MKHA is probably a consequence of the intensified transmembrane transport of lovastatin due to the direct action of bile acids on the cell membranes, as well as a result of their enhanced transport via specific bile acid transport systems.
authors.affiliation: Institute of Laboratory Medicine, Clinical Center of Voivodina, Novi Sad, Republic of Serbia. s.kojic@neobee.net
authors.forename: Suncica
authors.initials: S
authors.lastname: Kojic-Damjanov
authors.forename: Mirjana
authors.initials: M
authors.lastname: Djeric
authors.forename: Momir
authors.initials: M
authors.lastname: Mikov
authors.forename: Ksenija
authors.initials: K
authors.lastname: Kuhajda
authors.forename: Slavko
authors.initials: S
authors.lastname: Kevresan
mesh_terms: D000818:Animals; D000924:Anticholesteremic Agents / Q000494:pharmacology*; D001786:Blood Glucose / Q000378:metabolism; D002635:Chenodeoxycholic Acid / Q000031:analogs & derivatives* / Q000494:pharmacology; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D003921:Diabetes Mellitus, Experimental / Q000097:blood*; D008055:Lipids / Q000097:blood*; D008148:Lovastatin / Q000494:pharmacology*; D008297:Male; D051381:Rats; D017208:Rats, Wistar; D014280:Triglycerides / Q000097:blood
chemical_list: D000924:Anticholesteremic Agents; D001786:Blood Glucose; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D008055:Lipids; D014280:Triglycerides; D002635:Chenodeoxycholic Acid; C025576:3,7-dihydroxy-12-oxocholanoic acid; D008148:Lovastatin
references.citation: Atherosclerosis. 1998 Aug;139(2):291-9
references.pmid: 9712335
references.citation: J Lipid Res. 2003 May;44(5):943-52
references.pmid: 12562847
references.citation: Am J Physiol. 1991 Apr;260(4 Pt 1):G625-30
references.pmid: 2018137
references.citation: Toxicol Sci. 2005 Jan;83(1):114-25
references.pmid: 15496497
references.citation: Atherosclerosis. 2004 Aug;175(2):325-31
references.pmid: 15262189
references.citation: J Pharmacol Toxicol Methods. 2004 Nov-Dec;50(3):231-5
references.pmid: 15519910
references.citation: Br J Pharmacol. 2000 Nov;131(6):1179-87
references.pmid: 11082126
references.citation: Atherosclerosis. 1998 Sep;140(1):15-24
references.pmid: 9733211
references.citation: J Lipid Res. 2002 Jan;43(1):2-12
references.pmid: 11792716
references.citation: J Lipid Res. 1997 Feb;38(2):373-90
references.pmid: 9162756
references.citation: Carcinogenesis. 2007 May;28(5):940-6
references.pmid: 17183066
references.citation: Cancer Res. 2007 Feb 1;67(3):863-7
references.pmid: 17283114
references.citation: Farmaco. 2005 Nov-Dec;60(11-12):884-93
references.pmid: 16226752
references.citation: J Hepatol. 2006 Aug;45(2):337-8
references.pmid: 16793167
references.citation: J Hepatol. 2007 Sep;47(3):434-5
references.pmid: 17624466
references.citation: J Am Coll Cardiol. 2003 Sep 17;42(6):1091-7
references.pmid: 13678936
references.citation: Vascul Pharmacol. 2006 Feb;44(2):75-89
references.pmid: 16337220
references.citation: Gastroenterology. 1985 Jan;88(1 Pt 1):192-205
references.pmid: 2981081
references.citation: Biochim Biophys Acta. 1995 Jan 3;1254(1):7-12
references.pmid: 7811749
references.citation: Am J Cardiol. 2006 Apr 15;97(8):1198-205
references.pmid: 16616026
references.citation: Lipids. 1999 Dec;34(12):1327-32
references.pmid: 10652993
references.citation: J Mol Biol. 2007 Jun 1;369(2):439-50
references.pmid: 17434532
references.citation: Biochem Biophys Res Commun. 2007 Jun 8;357(3):707-11
references.pmid: 17448444
references.citation: Prostaglandins Other Lipid Mediat. 2005 May;76(1-4):59-73
references.pmid: 15967162
references.citation: Metabolism. 1999 May;48(5):618-26
references.pmid: 10337863
references.citation: Biochim Biophys Acta. 2005 Jun 15;1735(1):59-67
references.pmid: 15951237
references.citation: Int J Pharm. 2003 Jan 16;250(2):359-69
references.pmid: 12527163
references.citation: Eur J Pharm Sci. 2000 Apr;10(2):133-40
references.pmid: 10727879
references.citation: J Investig Med. 1995 Oct;43(5):443-50
references.pmid: 8528755
references.citation: Biochem Pharmacol. 2003 Aug 15;66(4):565-77
references.pmid: 12906921
references.citation: Hepatology. 2006 Aug;44(2):478-86
references.pmid: 16871584
references.citation: J Control Release. 2005 Jun 20;105(1-2):1-15
references.pmid: 15894393
references.citation: Free Radic Biol Med. 2006 Jun 1;40(11):2005-17
references.pmid: 16716901
references.citation: Proc Natl Acad Sci U S A. 1985 Nov;82(21):7419-23
references.pmid: 3903753
references.citation: Clin Chem. 1972 Jun;18(6):499-502
references.pmid: 4337382
references.citation: Pflugers Arch. 2004 Nov;449(2):123-31
references.pmid: 15578267
references.citation: FEBS Lett. 1999 Jun 11;452(3):160-4
references.pmid: 10386582
references.citation: Proc Natl Acad Sci U S A. 1980 Jul;77(7):3957-61
references.pmid: 6933445
references.citation: Toxicol Lett. 2001 Mar 31;120(1-3):369-77
references.pmid: 11323196
references.citation: Toxicol Sci. 2006 May;91(1):150-8
references.pmid: 16452108
references.citation: J Nutr Biochem. 2005 Dec;16(12):722-8
references.pmid: 16169202
references.citation: J Lipid Res. 1970 Nov;11(6):583-95
references.pmid: 4100998
references.citation: Digestion. 2004;70(2):79-83
references.pmid: 15375335
references.citation: J Lipid Res. 2002 Apr;43(4):533-43
references.pmid: 11907135
references.citation: J R Coll Physicians Edinb. 2002;32(2):134-42
references.pmid: 12434795
references.citation: Atherosclerosis. 1996 Jul;124(1):95-102
references.pmid: 8800497